- Companies
- Abridge
Abridge Revenue, Valuation, Funding & Investors
Abridge is valued at $5.3B as of June 2025, a 45.3x multiple on its last reported $117M revenue.
Last Abridge valuation
$5.3B
Series E · Jun 2025
Last Abridge funding round
Strategic investment
Amount undisclosed · Jun 2026
Abridge revenue
$117M
Series E · Jun 2025
Key investors in Abridge
Bessemer Venture Partners
Spark Capital
Union Square Ventures
Pillar VC
CVS Health Ventures
Lightspeed Venture Partners
About Abridge
Abridge is an AI-powered platform that converts patient-clinician conversations into structured clinical notes for electronic health records. Pittsburgh-based and founded in 2018, it serves over 100 health systems including UPMC and Mass General Brigham. The system uses generative AI to generate SOAP notes, discharge summaries, and billing codes, reducing documentation time by integrating with Epic and Cerner. Abridge processes millions of encounters annually, ensuring HIPAA compliance and supporting multilingual transcription across U.S. hospitals.
Founded
2018
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Revenue
$117M (Jun 2025)
Valuation
$5.3B (Jun 2025)
Abridge Valuation
Abridge is currently valued at $5.3B, based on its Series E in June 2025.
The $300M round was led by Andreessen Horowitz and Khosla Ventures.
Abridge's valuation has grown 6.2x from $850M at its Series C in February 2024 to $5.3B in June 2025, across 3 priced rounds.
Abridge valuation by funding round
Revenue multiple| Date | Stage | Valuation | Revenue Multiple |
|---|---|---|---|
| Jun 2025 | Series E | $5.3B | 45.3x |
| Feb 2025 | Series D | $2.8B | 52.9x |
| Feb 2024 | Series C | $850M | - |
Abridge Revenue
Abridge's latest recorded revenue is $117M, as of its Series E in June 2025. At a $5.3B valuation, that implies a 45.3x revenue multiple.
Revenue grew from $52M in February 2025 to $117M in June 2025, while the revenue multiple moved from 52.9x to 45.3x.
Abridge revenue by funding round
| Date | Revenue * | Valuation | Revenue Multiple | Stage |
|---|---|---|---|---|
| Jun 2025 | $117M | $5.3B | 45.3x | Series E |
| Feb 2025 | $52M | $2.8B | 52.9x | Series D |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
Abridge Funding History
Abridge has raised a total of $758M across 8 funding rounds.
Abridge's first fundraising round was a $5M seed round in November 2018. The most recent completed round was a strategic investment round in June 2026.
Abridge funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2026 | Strategic investment | Eli Lilly (lead) | - | - | - |
| Jun 2025 | Series E | Andreessen Horowitz (lead); Khosla Ventures (lead) | $300M | $5.3B | Abridge is a generative AI platform that converts medical conversations into clinically functional and billable documentation at the point of care. The company uses ambient AI technology to automate clinical note-writing for doctors and medical documentation, eliminating inefficiencies directly within the clinical conversation. Founded in 2018 and based in Pittsburgh, Abridge has become one of the leading ambient AI scribes in the healthcare sector. In June 2025, Abridge announced its Series E funding round of $300 million led by Andreessen Horowitz with participation from Khosla Ventures, bringing the company's post-money valuation to $5.3 billion. This round nearly doubled the company's valuation in just four months, following its $250 million Series D raise in February 2025 which valued the company at $2.75 billion. Abridge reported annualized recurring revenue of $117 million at the time of the Series E announcement. The company is trusted by more than 150 leading enterprise health systems across the United States, including major academic institutions and federally qualified health centers, serving conversations across 55 specialties and 28 languages. Abridge projects it will support clinicians across more than 50 million medical conversations in 2025 alone. The new capital will be used to scale the platform, expand its workforce, develop new products, build new capabilities in inpatient settings, and embed revenue cycle intelligence earlier in clinical conversations. The company reports that its technology reduces clinician burnout by up to 60-70 percent. Abridge has raised more than $800 million in total funding since its founding and has been a major driver of venture capital activity in Pittsburgh, accounting for nearly half of the city's $689 million raised in Q1 2025. |
| Feb 2025 | Series D | Elad Gil (lead); IVP (lead); Redpoint; SV Angel; Spark Capital; NVentures; Bessemer Venture Partners; CapitalG; Lightspeed Venture Partners; CVS Health Ventures; K. Ventures; California HealthCare Foundation | $250M | $2.8B | Abridge, a Pittsburgh-based generative AI startup founded in 2018, develops an enterprise-grade platform that transcribes and converts patient-clinician conversations into structured, billable clinical documentation in real-time, supporting over 28 languages and 50 specialties across outpatient, emergency, and inpatient settings. The platform integrates with EHR systems to reduce clinician burnout, improve patient experiences, and streamline revenue cycle processes through features like the new Contextual Reasoning Engine, which incorporates prior patient data and health system guidelines for accurate billing notes. As of February 2025, Abridge has deployed its technology in over 100 major U.S. health systems, including Kaiser Permanente (with 25,000+ clinicians, 40 hospitals, and 600+ offices), Akron Children's Hospital, and Memorial Sloan Kettering Cancer Center. On February 17, 2025, Abridge closed a $250 million Series D funding round co-led by Elad Gil and IVP, with participation from Bessemer Venture Partners, California HealthCare Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures (NVIDIA's venture arm), Redpoint Ventures, Spark Capital, and SV Angel. The post-money valuation reached $2.75 billion, following a $150 million Series C in February 2024. Proceeds will fund AI research and development, including foundation models, and commercial expansion to more health systems. The round coincides with product advancements like the Contextual Reasoning Engine, aimed at enhancing documentation for billing efficiency and long-term partnerships with health systems. CEO Shiv Rao emphasized the investment's role in differentiating Abridge's AI approach for sustained value in clinical and financial workflows. Abridge showcased at ViVE 2025 in Nashville and has attracted attention from figures like Rick Rubin and Gabby Thomas, signaling growing industry prominence in ambient AI for medical notetaking. |
| Feb 2024 | Series C | Lightspeed Venture Partners (lead); Redpoint (lead); IVP; Kaiser Permanente Ventures; Spark Capital; Union Square Ventures; Wittington Ventures; Bessemer Venture Partners; CVS Health Ventures; Mass General Brigham | $150M | $850M | Abridge is a generative AI platform that transforms medical conversations into clinically useful and billable documentation at the point of care, reducing clinician burnout with deep EHR integration, support for over 50 specialties, and 28+ languages. The company raised a $150 million Series C round in February 2024, backed by investors including Lightspeed Venture Partners, Redpoint, Bessemer Venture Partners, CVS Health Ventures, IVP, Kaiser Permanente Ventures, Spark Capital, Union Square Ventures, Mass General Brigham, and Wittington Ventures, with Lightspeed and Redpoint as leads. This funding supported expansion amid growing adoption in over 100 health systems by early 2025, including major deployments at Duke Health, Johns Hopkins, Mayo Clinic, Kaiser Permanente, and others, automating 91% of note creation and processing millions of conversations. Post-2024, Abridge accelerated growth with a $250 million Series D in February 2025 co-led by Elad Gil and IVP, valuing the company at approximately $2.75-2.8 billion post-money, followed by a $300 million Series E in June 2025 led by Andreessen Horowitz at $5.3 billion valuation. These rounds funded advancements like the Contextual Reasoning Engine for revenue cycle integration, AI-assisted coding, and inpatient workflows, positioning Abridge as a leader in AI medical scribing integrated with Epic systems. Traction metrics emerged later: Sacra estimated $60M ARR at end-2024, reaching $100M in May 2025 and $117M contracted ARR in Q1 2025 from enterprise subscriptions at ~$2,500 per clinician/year, serving 150+ health systems and 50 million conversations annually by mid-2025. |
| Oct 2023 | Series B | Spark Capital (lead); LifePoint Health; American College of Cardiology; Kaiser Permanente Ventures; UCOP; Bessemer Venture Partners; SCAN Group; CVS Health Ventures; Mayo Clinic | $30M | - | Abridge is a Pittsburgh-based generative AI platform that converts patient-clinician conversations into structured clinical notes and billable documentation at the point of care, aiming to reduce clinician burnout and administrative burden. The company announced a $30 million Series B funding round on October 26, 2023, led by Spark Capital, with participation from Bessemer Venture Partners, CVS Health Ventures, Kaiser Permanente Ventures, LifePoint Health, Mayo Clinic, SCAN Group, UC Investments (University of California), and the American College of Cardiology. This brought total funding to $62.5 million since founding in 2018. The investment supports large-scale health system rollouts and product advances to enhance value for patients, clinicians, and health systems. Abridge's technology leverages explainable AI to map summaries to ground truth, enabling quick verification by providers. At the time, it was used by thousands of doctors across health systems, improving care for hundreds of thousands of patients via a consumer app. Customers praised its focus on clinical workflows and AI-native talent. Following the Series B, Abridge rapidly scaled with a $150 million Series C in early 2024 led by Lightspeed Venture Partners and Redpoint Ventures, including many of the same investors, bringing total funding to $212.5 million. A $250 million Series D followed in October 2024/February 2025 co-led by Elad Gil and IVP, with Lightspeed, NVentures (NVIDIA), and others, achieving $2.5 billion pre-money valuation (up from ~$200M in 2023) or $2.75 billion post-money, and total funding over $450 million. The platform expanded to 100+ health systems, 28+ languages, 50+ specialties, and EHR integrations across care settings. |
| Aug 2022 | Series A | Wittington Ventures (lead); Union Square Ventures; Pillar VC; Whistler Capital Partners; Bessemer Venture Partners; UPMC Enterprises; Yoshua Bengio | $13M | - | Abridge is a Pittsburgh-based company developing medical conversation AI to combat physician burnout and automate documentation workflows. In November 2022, it announced an oversubscribed $12.5M Series A-1 funding round led by Wittington Ventures, with participation from existing investors Union Square Ventures, Bessemer Venture Partners, Pillar Venture Capital, UPMC Enterprises, and new investors Yoshua Bengio and Whistler Capital Partners. The round brought Abridge's total funding to $27 million. The capital supports team growth and research and development to improve documentation solutions. Abridge differentiates with natural conversation processing, seamless integrations with health technology infrastructure like Twilio, Genesys, and Vonage, and high accuracy without wakewords. |
| Oct 2020 | Series A | Union Square Ventures (lead); UPMC (lead); Zen Chu; Pillar VC; KdT Ventures; Bessemer Venture Partners; Esther Dyson; ANEESH P. CHOPRA | $10M | - | - |
| Nov 2018 | Seed | Pillar VC; KdT Ventures | $5M | - | - |
Who has invested in Abridge?
33 investors have backed Abridge across its funding rounds, including Bessemer Venture Partners, Spark Capital, Union Square Ventures, Pillar VC, CVS Health Ventures and Lightspeed Venture Partners.
Lead investors include Eli Lilly, Andreessen Horowitz, Khosla Ventures, Elad Gil, IVP and 6 other investors.
Abridge Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 5 | Participant | Oct 2020 | ||
| 3 | Lead | Oct 2023 | ||
| 3 | Lead | Oct 2020 | ||
| 3 | Participant | Nov 2018 | ||
| 3 | Participant | Oct 2023 | ||
| 2 | Lead | Feb 2024 | ||
| 2 | Lead | Feb 2024 | ||
| 2 | Participant | Oct 2023 | ||
| 2 | Lead | Aug 2022 | ||
| 2 | Participant | Nov 2018 | ||
| 2 | Lead | Feb 2024 | ||
| 1 | Participant | Oct 2023 | ||
| 1 | Participant | Oct 2020 | ||
This data is available for Pro users. Sign up to see all 33 Abridge investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbridge Competitors
Abridge competitors include listed companies like Tempus AI and Waystar, and private ones like Commure, Doctolib, Sword Health and Synthesia.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $200M | - | $7B | 35.0x | ||
| Private | $400M | - | $6.4B | 16.0x | ||
| Private | $240M | - | $4B | 16.7x | ||
| Private | $100M | - | $4B | 40.0x | ||
| Publicly listed | $1.3B | ($131M) | $15B | 10.1x | ||
| Publicly listed | $1.1B | $390M | $5.1B | 5.2x |
Abridge Public Comps
Abridge is still privately-owned, but its public comps include Waystar, Presight AI, Doximity, SenseTime Group, Tenable, CCC Intelligent Solutions, XtalPi, CorVel, UiPath and Fermi.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.1B | $390M | 5.8x | 5.2x | 16.3x | 12.3x | |||
| $825M | $214M | 6.3x | 5.4x | 24.4x | 20.8x | |||
| $645M | $229M | 6.3x | 6.2x | 17.7x | 11.9x | |||
| $748M | ($70M) | 6.9x | 5.8x | (73.5x) | 113.7x | |||
| $999M | $31M | 4.1x | 3.9x | 129.9x | 15.3x | |||
| $1.1B | $238M | 4.8x | 4.5x | 21.5x | 10.8x | |||
| $120M | $22M | 24.8x | 21.5x | 134.0x | (141.6x) | |||
| $959M | $175M | 3.5x | - | 19.1x | - | |||
This data is available for Pro users. Sign up to see all Abridge competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Abridge
| When was Abridge founded? | Abridge was founded in 2018. |
| Where is Abridge headquartered? | Abridge is headquartered in Pittsburgh, PA, United States. |
| Is Abridge publicly listed? | No, Abridge is a private, VC-backed company. |
| What is Abridge's valuation? | Abridge was last valued at $5.3B in its Series E in June 2025. |
| How much funding has Abridge raised? | Abridge has raised $758M across 8 funding rounds. |
| What was Abridge's last funding round? | Abridge's last funding round was a strategic investment round in June 2026, led by Eli Lilly. |
| Who are Abridge's investors? | Abridge's investors include Bessemer Venture Partners, Spark Capital, Union Square Ventures, Pillar VC, CVS Health Ventures, Redpoint, IVP, Kaiser Permanente Ventures, Wittington Ventures, KdT Ventures and 23 others. |
| What is Abridge's revenue? | Abridge's latest recorded revenue is $117M (June 2025). |
| What is Abridge's revenue multiple? | Abridge's latest valuation implies a 45.3x revenue multiple ($5.3B valuation on $117M of revenue). |
| Which companies are comparable to Abridge? | Companies comparable to Abridge include Commure, Doctolib, Sword Health, Synthesia, Tempus AI and Waystar. |
See companies similar to Abridge
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




